-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARD-501 in Autism Spectrum Disorder (ASD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARD-501 in Autism Spectrum Disorder (ASD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARD-501 in Autism Spectrum Disorder (ASD) Drug Details: ARD-501 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zolbetuximab in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zolbetuximab in Gastric Cancer Drug Details: Zolbetuximab (claudiximab, IMAB-362) is under development for the treatment...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRF-6021 in Parkinson’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GRF-6021 in Parkinson's Disease Drug Details: GRF-6021 is under development for the treatment of Parkinson's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XYF-13 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XYF-13 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.XYF-13 in Recurrent Glioblastoma Multiforme (GBM) Drug Details:XYF-13 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VCTX-211 in Type 1 Diabetes (Juvenile Diabetes)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.VCTX-211 in Type 1 Diabetes (Juvenile Diabetes) Drug Details:VCTX-211 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRF-6019 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GRF-6019 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GRF-6019 in Parkinson's DiseaseDrug Details:GRF-6019 is under development for the treatment of mild...